INVO Fertility, Inc. (IVF) 股票分析

公司概述

INVO Fertility, Inc. operates as a healthcare services company dedicated to the fertility marketplace, delivering assisted reproductive technology care through its distinct segments of Fertility Clinic Services, INVOcell Device, and Therapeutics. The company's core product offering includes the INVOcell Device, a specialized medical instrument designed to support patient treatment within this high-precision industry. This entity functions within the broader Healthcare sector, specifically categorized under the Medical Devices industry, which necessitates adherence to rigorous regulatory standards and technological innovation. As of the latest reporting period, the company maintains a market capitalization of $13.99M, generates annual revenue of $6.94M, and employs a workforce of 33 individuals. These financial metrics indicate that INVO Fertility, Inc. operates as a small-cap enterprise with a relatively modest revenue base, reflecting its niche position in the specialized fertility treatment market rather than broad consumer demand.

财务健康

The company reported a total revenue of $6.94M for the trailing twelve months, yet this figure masks a significant operational challenge with a net income of -$11,220,118 and an EBITDA of -$7,119,142. The substantial negative gap between the $6.94M revenue and the -$11,220,118 net income reveals a cost structure burdened by high operating expenses or non-operating costs that severely erode profitability. Despite the negative earnings, the firm generated positive free cash flow of $950,669, which suggests a degree of financial flexibility allowing for capital retention or debt servicing despite accounting losses. Profitability analysis shows a gross margin of 39.2%, indicating moderate efficiency in production and supply chain costs, while the operating margin stands at -93.1% and the profit margin is 0.0%, highlighting severe operational inefficiencies or one-time charges impacting bottom-line results. The balance sheet presents a leveraged position with total debt of $4.23M against cash holdings of $355,891, resulting in a debt-to-equity ratio of 72.39. This disparity indicates a highly leveraged balance sheet where debt obligations significantly outweigh liquid assets. Liquidity is constrained further by a current ratio of 0.12, which signals that current liabilities exceed current assets, raising concerns about short-term solvency. Return on Equity and Return on Assets are both reported as N/A due to the negative equity base, but the Return on Assets metric is explicitly stated as -48.4%, revealing that management is generating negative returns on the company's asset base.

估值评估

Valuation multiples for INVO Fertility, Inc. reflect its unprofitable status, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.09. The negative forward P/E ratio implies that analysts project continued negative earnings in the near future, preventing the use of traditional earnings-based valuation models. The price-to-book ratio is recorded at -0.09, indicating that the market capitalization is negative relative to the book value, a condition often found in companies with significant accumulated deficits or negative shareholder equity. Alternative valuation metrics such as the price-to-sales ratio of 2.01 and an EV/EBITDA of -1.90 provide the only viable frameworks for assessing the stock's worth, suggesting the market values the company based on revenue generation rather than earnings power. Price action over the past year has been volatile, with a 52-week high of $384.00 and a 52-week low of $1.93. Without a specific current share price in the provided facts, the trading range highlights extreme volatility, with the stock capable of fluctuating between a high of $384.00 and a low of $1.93 within a single trading year. The Beta value is listed as N/A, meaning volatility data relative to the broader market index is not available for this specific security in the current dataset.

Growth & Income

Revenue growth for the trailing twelve months stands at 22.6%, demonstrating a strong expansion in top-line sales, whereas earnings growth is listed as N/A due to the company's negative income history. The divergence between positive revenue growth and the absence of earnings growth implies that the company is reinvesting its expanding revenue base into operations to achieve future profitability rather than distributing profits. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings are theoretically reinvested back into the business or used to service debt given the current negative net income. The overall growth and income profile is characterized by top-line expansion coupled with a lack of income generation and dividend distribution, relying entirely on operational turnaround to unlock shareholder value.